Search

Search Constraints

You searched for: Author/Creator Pianko, Stephen

Search Results

1. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+). Issue 5 (4th March 2016)

2. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure. Issue 4 (30th January 2018)

3. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Issue 6 (30th October 2017)

4. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. (20th December 2017)

5. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon‐α. Issue 5 (25th April 2013)

6. Immunomodulator use does not prevent first loss of response to anti‐tumour necrosis factor alpha therapy in inflammatory bowel disease: long‐term outcomes in a real‐world cohort. Issue 6 (11th June 2019)

7. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Issue 10215 (14th December 2019)

8. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Issue 10215 (14th December 2019)

9. Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REV1TAL Study. Issue 8 (November 2017)